Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: In vivo and in vitro studies

  • Authors:
    • Georgios Karanikas
    • Herbert Ulrich-Pur
    • Alexander Becherer
    • Karoline Wiesner
    • Robert Dudczak
    • Markus Raderer
    • Kurt Kletter
  • View Affiliations

  • Published online on: March 1, 2002     https://doi.org/10.3892/or.9.2.353
  • Pages: 353-357
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Radiolabeled human non-specific polyclonal immunoglobulin G (HIG), is used for the diagnosis of inflammation/infection. Focal uptake of HIG in malignant lesions has also been reported. We investigated the diagnostic value of In-111-HIG in patients with known pancreatic cancer. Fourteen consecutive patients with histologically verified pancreatic cancer were included in this prospective study. Four of them had undergone potentially curative surgery for their primary cancer. Eight patients had liver metastases. Planar and SPECT images of the abdomen were performed after administration of In-111-HIG (74-92 MBq). Scintigraphic results were compared to conventional imaging by means of CT scanning. In addition, In-111-HIG uptake was investigated in a panel of four representative human pancreatic cancer cell lines. Primary pancreatic tumors were visualized by In-111-HIG in 6 out of 10 patients (sensitivity 60%), while 1 was false positive. In comparison, CT scanning was true positive in 9 out of 10 patients (sensitivity 90%), and no false positive. Visualization of liver lesions by means of In-111-HIG was possible in 6 out of 8 patients (sensitivity 75%), while 1 was false positive. In vitro studies revealed only minimal uptake of In-111-HIG into cells (about 3% of activity). Our data demonstrate that In-111-HIG is able to visualize pancreatic primary cancers as well as liver metastases. However, the minimal uptake into tumor cells, as shown in vitro, suggests non-specific tumor related inflammatory reactions, increased vascular permeability, release of indium from In-111-DTPA-labeled antibody and local retention to be responsible for visualization of the tumor site.

Related Articles

Journal Cover

March-April 2002
Volume 9 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Karanikas G, Ulrich-Pur H, Becherer A, Wiesner K, Dudczak R, Raderer M and Kletter K: Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: In vivo and in vitro studies. Oncol Rep 9: 353-357, 2002
APA
Karanikas, G., Ulrich-Pur, H., Becherer, A., Wiesner, K., Dudczak, R., Raderer, M., & Kletter, K. (2002). Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: In vivo and in vitro studies. Oncology Reports, 9, 353-357. https://doi.org/10.3892/or.9.2.353
MLA
Karanikas, G., Ulrich-Pur, H., Becherer, A., Wiesner, K., Dudczak, R., Raderer, M., Kletter, K."Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: In vivo and in vitro studies". Oncology Reports 9.2 (2002): 353-357.
Chicago
Karanikas, G., Ulrich-Pur, H., Becherer, A., Wiesner, K., Dudczak, R., Raderer, M., Kletter, K."Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: In vivo and in vitro studies". Oncology Reports 9, no. 2 (2002): 353-357. https://doi.org/10.3892/or.9.2.353